3-苯基-2-吡啶甲酸 | 103863-15-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-苯基-2-吡啶甲酸
• 中文别名: 3-苯基-2-吡啶羧酸
• 英文名称: 3-phenylpicolinic acid
• 英文别名: 3-phenylpyridine-2-carboxylic acid
• CAS: 103863-15-6
• 化学式: C₁₂H₉NO₂
• 分子量: 199.209
• InChiKey: SJLPJJGKJSOUOR-UHFFFAOYSA-N

物化性质

• 熔点：
  325-328℃
• 沸点：
  367℃
• 密度：
  1.241
• 闪点：
  176℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P332+P313
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Phenylpicolinic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Phenylpicolinic acid
CAS number: 103863-15-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H9NO2
Molecular weight: 199.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-苯基-2-吡啶甲酸 在 polyphosphoric acid 作用下， 反应 5.0h， 以40%的产率得到indeno[2,1-b]pyridin-9-one
  参考文献：
  名称：

  引入氮杂螺双芴以形成α-，β-，γ-和δ-氮杂9,9'-螺双芴：新型双极体系，用于高效的蓝色有机发光二极管

  摘要：

  合成了四个在一个芴部分的不同位置带有氮原子的aza-9,9'-spirbibifluorenes（aza-SBFs），以研究其结构性质之间的关系。α-Aza-SBF和β-aza-SBF几乎完全分开了最高占据分子轨道（HOMO）和最低未占据分子轨道（LUMO），而γ-aza-SBF和δ-aza-SBF显示出HOMO和LUMO重叠轨道。氮杂-SBF比SBF表现出优异的双极性特性和良好的热稳定性。α-，β-，γ-和δ-aza-SBF的最大电流效率（CE）的OLED分别为28.8、24.9、25.5和27.2 cd / A。与SBF相比，所有四个aza-SBF均显示出更好的器件性能。基于α-氮杂-SBF的OLED的CE和功率效率（PE）为28.8 cd / A和22.6 lm / W，而基于SBF的OLED仅为12.3 cd / A和8.2 lm / W。基于氮-氮杂-SBF的OLED的最大外部量子效率为15

  DOI：

  10.1016/j.dyepig.2018.03.066
• 作为产物：
  描述：

  3-溴-2-吡啶甲酸甲酯 在 sodium hydroxide 、 二(氰基苯)二氯化钯 、 sodium carbonate 、 1,4-双(二苯基膦)丁烷 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 19.0h， 生成 3-苯基-2-吡啶甲酸
  参考文献：
  名称：

  9-Hydroxyazafluorenes and Their Use in Thrombin Inhibitors

  摘要：

  Optimization of a previously reported thrombin inhibitor, 9-hydroxy-9-fluorenylcarbonyl-l-prolyl-trans-4-aminocyclohexylmethylamide (1), by replacing the aminocyclohexyl P1 group provided a new lead structure, 9-hydroxy-9-fluorenylcarbonyl-l-prolyl-2-aminomethyl-5-chlorobenzylamide (2), with improved potency (K(i) = 0.49 nM for human thrombin, 2x APTT = 0.37 microM in human plasma) and pharmacokinetic properties (F = 39%, iv T(1/2) = 13 h in dogs). An effective strategy for reducing plasma protein binding of 2 and improving efficacy in an in vivo thrombosis model in rats was to replace the lipophilic fluorenyl group in P3 with an azafluorenyl group. Systematic investigation of all possible azafluorenyl P3 isomers and azafluorenyl-N-oxide analogues of 2 led to the identification of an optimal compound, 3-aza-9-hydroxyfluoren-9(R)-ylcarbonyl-l-prolyl-2-aminomethyl-5-chlorobenzylamide (19b), with high potency (K(i) = 0.40 nM, 2x APTT = 0.18 microM), excellent pharmacokinetic properties (F = 55%, T(1/2) = 14 h in dogs), and complete efficacy in the in vivo thrombosis model in rats (inhibition of FeCl(3)-induced vessel occlusions in six of six rats receiving an intravenous infusion of 10 microg/kg/min of 19b). The stereochemistry of the azafluorenyl group in 19b was determined by X-ray crystallographic analysis of its N-oxide derivative (23b) bound in the active site of human thrombin.

  DOI：

  10.1021/jm049423s

文献信息

• [EN] DISUBSTITUTED OCTAHY-DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS<br/>[FR] OCTAHYDROPYRROLO [3,4-C] PYRROLES DISUBSTITUÉS UTILISÉS COMME MODULATEURS DU RÉCEPTEUR DE L'OREXINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2012145581A1

  公开（公告）日：2012-10-26

  Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  描述了二取代的八氢吡咯[3,4-c]吡咯化合物，这些化合物可用作促进睡眠素受体的调节剂。这些化合物可能在药物组合物和治疗由促进睡眠素活性介导的疾病状态、紊乱和病况的方法中有用，比如失眠。
• Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer
  作者：Bruce D. Dorsey、Mohamed Iqbal、Sankar Chatterjee、Ernesto Menta、Raffaella Bernardini、Alberto Bernareggi、Paolo G. Cassarà、Germano D’Arasmo、Edmondo Ferretti、Sergio De Munari、Ambrogio Oliva、Gabriella Pezzoni、Cecilia Allievi、Ivan Strepponi、Bruce Ruggeri、Mark A. Ator、Michael Williams、John P. Mallamo

  DOI：10.1021/jm7010589

  日期：2008.2.1

  malignant cells. The successful development of the 20S human proteasome inhibitor bortezomib for the treatment of relapsed and refractory multiple myeloma has established this targeted intervention as an effective therapeutic strategy. Herein, the potent, selective, and orally bioavailable threonine-derived 20S human proteasome inhibitor that has been advanced to preclinical development, [(1R)-1-[[(2 S,3

  泛素-蛋白酶体途径在调节细胞蛋白的产生和破坏中起关键作用。这些途径介导增殖和细胞存活，特别是在恶性细胞中。用于治疗复发性和难治性多发性骨髓瘤的20S人类蛋白酶体抑制剂硼替佐米的成功开发已将这种靶向干预确立为有效的治疗策略。在本文中，有效，选择性和口服生物利用的苏氨酸来源的20S人蛋白酶体抑制剂已被推进到临床前开发，[（1R）-1-[[（2 S，3 R）-3-hydroxy-2-[[公开了6-苯基吡啶-2-羰基氨基] -1-氧丁基]氨基] -3-甲基丁基]硼酸20（CEP-18770）。
• [EN] DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS<br/>[FR] OCTAHYDROPYRROLO[3,4-C]PYRROLES DISUBSTITUÉS EN TANT QUE MODULATEURS DE RÉCEPTEUR D'OREXINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011050198A1

  公开（公告）日：2011-04-28

  Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  描述了二取代的八氢吡咯并[3,4-c]吡咯化合物，这些化合物可用作促进睡眠素受体的调节剂。这些化合物可能在药物组合物和治疗由促进睡眠素活性介导的疾病状态、紊乱和症状的方法中有用，比如失眠。
• 신규한 유기화합물, 상기 유기화합물을 포함하는 유기 전계발광 소자용 재료 및 유기 전계발광 소자
  申请人：NANJING TOPTO MATERIALS CO., LTD. 난징고광반도체재료유한회사(520150650957)

  公开号：KR20200108163A

  公开（公告）日：2020-09-17

  본 발명은 화학식 1로 표시되는 신규한 유기화합물, 상기 유기화합물을 포함하는 유기 전계발광 소자용 재료 및 유기 전계발광 소자를 제공한다.

  本发明提供了一种被表示为化学式1的新有机化合物，以及用于有机电致发光器件的材料和有机电致发光器件，其中包括所述有机化合物。
• [EN] NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES<br/>[FR] NOUVEAUX N-[(PYRIMIDINYLAMINO)PROPANYL]- ET N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2017178341A1

  公开（公告）日：2017-10-19

  The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

  本发明涉及新颖的N-[(嘧啶基氨基)丙基]-和N-[(吡嗪基氨基)丙基]芳基甲酰胺衍生物，其制备方法，含有它们的药物组合物以及它们在治疗中的应用，特别是在与促觉醒素亚型1受体有关的疾病的治疗或预防中的应用。